You are here: Industry Insights > Market News > Alembic’s Doxycycline capsules receives US FDA approval

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Alembic’s Doxycycline capsules receives US FDA approval

expressbpdAugust 01, 2017

Tag: Alembic , Doxycycline capsules , FDA Approval

Favorites

Alembic Pharmaceuticals has received the United States Food and Drug Administration (US FDA) approval for Abbreviated New Drug Application (ANDA) of anti-bacterial Doxycycline capsules USP 75 mg and 100 mg.

The approved ANDA is therapeutically equivalent to a reference listed drug product Monodox capsules, 75 mg and 100 mg of Aqua Pharmaceuticals. Doxycycline capsules are used in the treatment and prevention of infections that are proved or strongly suspected to be caused by bacteria.

According to IMS December 2016 data, Doxycycline capsules had an estimated market size of $30 million. The company now has 62 ANDA approvals from the US FDA.

Previous:FDA wants to reduce the amount of nicotine in cigarettes

Next:Dr Rao VSV Vadlamudi elected as President of CPA

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Alembic’s Doxycycline capsules receives US FDA approval | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Alembic’s Doxycycline capsules receives US FDA approval

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Alembic’s Doxycycline capsules receives US FDA approval

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>